secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2023-10-30T23:59:59+00:00
Accession:  0001437749-23-029312
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zevra/Acer merger supplement filed; shareholder lawsuits prompt additional disclosures
--------------------------------------------------------------------------------

- Three stockholder lawsuits filed (S.D.N.Y. and D. Del.) alleging proxy omissions; demand letters received.
- Acer voluntarily supplements proxy statement on Oct. 30 to address litigation risks, without admitting materiality.
- Supplement adds details: no standstill provisions in confidentiality agreements, no officer/director employment offers from Zevra.
- Updated financial analyses: DCF terminal growth rate of -80%; implied equity values $0.90-$2.71 (Plan 1) and $1.13-$3.63 (Plan 2).
- Acer board continues to unanimously recommend stockholder vote 'FOR' the merger at Nov. 8 special meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000143774923029312/0001437749-23-029312-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000143774923029312/zvra20231027_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-029312

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer